Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v23-EN Version v14-FR
Language English French
Date Updated 2022-07-20 2022-05-11
Drug Identification Number 02350106 02350106
Brand name ACTEMRA ACTEMRA
Common or Proper name ACTEMRA ACTEMRA
Company Name HOFFMANN-LA ROCHE LIMITED HOFFMANN-LA ROCHE LIMITED
Ingredients TOCILIZUMAB TOCILIZUMAB
Strength(s) 200MG 200MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS
Packaging size 200MG/10ML 1VIAL 200MG/10ML 1VIAL
ATC code L04AC L04AC
ATC description IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date 2022-07-15 2022-05-30
Actual start date
Estimated end date 2022-07-30 Unknown
Actual end date 2022-06-22
Shortage status Avoided shortage Anticipated shortage
Tier 3 Status No Yes
Company comments
Health Canada comments